Mode
Text Size
Log in / Sign up

Hypofractionated Radiotherapy Shows High Disease Control in Melanoma Brain MetastasesCan a gentler radiation schedule help control melanoma that has spread to the brain?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider hypofractionated radiotherapy for melanoma brain metastases in selected cases, but recognize evidence is from a small retrospective study.

A retrospective cohort study at a single center evaluated 26 patients with melanoma brain metastases who received hypofractionated radiotherapy (HFRT) regimens of 30 Gy/5 fractions, 36 Gy/6 fractions, or 42 Gy/7 fractions. The primary outcome was local control assessed 1–3 months post-treatment, with secondary outcomes including intracranial progression-free survival (IPFS), overall survival (OS), and adverse events. Median follow-up was 7.5 months.

At the 3-month assessment, the disease control rate was 96%, comprising 2 complete responses, 16 partial responses, and 7 cases of stable disease. Median OS was 10.5 months, and median IPFS was 4.5 months. In the 11 patients with baseline intracranial hemorrhage, hemorrhage reduction was observed in 100% of cases.

No grade ≥3 adverse events or symptomatic radiation necrosis occurred during follow-up. No radiotherapy-related intracranial hemorrhage or exacerbation of pre-existing hemorrhage was observed. The study reported no serious adverse events or treatment discontinuations.

Key limitations include the retrospective design, single-center setting, and small sample size of 26 patients. No comparator group was reported, preventing direct efficacy or safety comparisons to stereotactic radiosurgery or other treatments. The practice relevance is restrained: while HFRT may offer an alternative in selected high-risk scenarios, these findings require validation in larger, prospective studies.

Facing melanoma that has spread to the brain is a daunting challenge, and finding effective treatments with tolerable side effects is critical. A small, single-center study looked back at 26 patients who received a specific type of multi-session radiation therapy. The goal was to see if this approach could control the brain tumors while being gentle enough to avoid serious complications, especially in tumors that were already bleeding.

The results were encouraging for this specific group. At the first check-up a few months after treatment, 96% of the treated tumors were either shrinking or stable. For the patients overall, the brain tumors were controlled for a median of 4.5 months, and patients lived for a median of 10.5 months after treatment. Importantly, no one experienced severe side effects or a dangerous brain swelling called symptomatic radiation necrosis during the follow-up period. In a promising finding for 11 patients whose tumors were bleeding, the radiation appeared to stop the bleeding in every case.

It's crucial to understand what this study does and doesn't tell us. Because it was a small, retrospective look back at patient records from one hospital, we can't say for sure that the radiation caused these outcomes. There was no comparison group to show if this approach is better or worse than other treatments. The follow-up time was relatively short, at a median of 7.5 months. While these early findings are a positive signal, they highlight the need for larger, more rigorous studies to see if this approach holds up.

What this means for you:
Early data shows a multi-session radiation schedule may help control melanoma brain tumors with manageable side effects.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and purposeMelanoma brain metastasis (MBM) is associated with a poor prognosis and a high risk of intracranial hemorrhage (ICH), which may complicate the use of stereotactic radiosurgery (SRS). This study evaluated the efficacy and safety of hypofractionated radiotherapy (HFRT) for MBM, with a specific focus on metastases with hemorrhagic components.Patients and methodsIn this single-center retrospective study, 26 patients with MBMs received HRT regimens of 30 Gy/5 fractions, 36 Gy/6 fractions, or 42 Gy/7 fractions. The primary endpoint was the local control (LC) rate assessed on the first MRI evaluation after radiotherapy completion (1–3 months after radiotherapy completion). Secondary endpoints included intracranial progression-free survival (IPFS), overall survival (OS), and treatment-related adverse events (AEs).ResultsThe disease control rate was 96% at the 3-month assessment (2 complete responses, 16 partial responses, 7 stable disease). The median OS was 10.5 months and the median IPFS was 4.5 months. No grade ≥3 AEs or symptomatic radiation necrosis occurred during the follow-up period (median 7.5 months). Notably, no radiotherapy-related ICH or exacerbation of pre-existing hemorrhage was observed, and hemorrhage reduction was achieved in all 11 patients with baseline ICH (100%).ConclusionHFRT demonstrated promising local control and a favorable safety profile in this cohort of MBM patients, It shows particular potential for treating hemorrhagic metastases and may offer a valuable alternative to SRS in selected high-risk scenarios, meriting further investigation in larger studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.